# A First in Human, Single Dose, Safety and Tolerability Study of MKC253 Inhalation Powder in Healthy Adult Males

> **NCT00475371** · PHASE1 · COMPLETED · sponsor: **Mannkind Corporation** · enrollment: 26 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2
- Healthy Males

## Interventions

- **DRUG:** MKC253 Inhalation Powder

## Key facts

- **NCT ID:** NCT00475371
- **Lead sponsor:** Mannkind Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-04
- **Primary completion:** 2007-06
- **Final completion:** —
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2012-06-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00475371

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00475371, "A First in Human, Single Dose, Safety and Tolerability Study of MKC253 Inhalation Powder in Healthy Adult Males". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00475371. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*